[PDF][PDF] Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
A O'Donnell, S Faivre, HA Burris III, D Rea… - Journal of Clinical …, 2008 - researchgate.net
A O'Donnell, S Faivre, HA Burris III, D Rea, V Papadimitrakopoulou, N Shand, HA Lane…
Journal of Clinical Oncology, 2008•researchgate.netPhase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of
Rapamycin Inhibitor Everolimus in Patients Wit Page 1 Phase I Pharmacokinetic and
Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in
Patients With Advanced Solid Tumors Anne O’Donnell, Sandrine Faivre, Howard A. Burris III,
Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell,
Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, and Ian Judson …
Rapamycin Inhibitor Everolimus in Patients Wit Page 1 Phase I Pharmacokinetic and
Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in
Patients With Advanced Solid Tumors Anne O’Donnell, Sandrine Faivre, Howard A. Burris III,
Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell,
Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, and Ian Judson …
Purpose
To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001).
researchgate.net